Groundbreaking Phase III topline results for Sparsentan in Japanese IgA nephropathy patients Renalys Pharma has announced positive topline results from a Phase III study evaluating sparsentan in Japanese patients with IgA nephropathy. The trial, conducted in a cohort of 35 patients, focused on the primary endpoint of the percent change from baseline in the 24-hour…